人类疫苗佐剂市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围:按类型、应用(流感、肝炎、人类乳头状瘤病毒等)、最终用户和地理位置
市场调查报告书
商品编码
1424141

人类疫苗佐剂市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围:按类型、应用(流感、肝炎、人类乳头状瘤病毒等)、最终用户和地理位置

Human Vaccine Adjuvants Market Size and Forecast, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), End User, and Geography

出版日期: | 出版商: The Insight Partners | 英文 199 Pages | 订单完成后即时交付

价格

全球人用疫苗佐剂市场预计将从2022年的15.71亿美元增至2030年的44.89亿美元。预计2022年至2030年该市场将以14.0%的CAGR增长。推动人用疫苗佐剂市场成长的关键因素包括慢性病盛行率上升以及对免疫计划的日益关注。

人用疫苗佐剂市场的市场机会

不断扩大的製药业预计将对佐剂的需求产生积极影响,因为它们可以提高疫苗的功效和安全性。製药业日益关注传染病、癌症和自体免疫疾病,为开发针对这些特定疾病领域的个人化疫苗和佐剂提供了平台。这为佐剂製造商提供了开发专门佐剂以增强对这些疾病疫苗的免疫反应的机会。

美国拥有全球研发最密集的製药业之一。根据欧洲製药工业协会联合会(EFPIA)的数据,北美市场(美国和加拿大)仍然是全球最大市场,份额为 49.1%,远远领先欧洲、中国和日本。美国是创新研发投资的全球领导者,在过去十年中,该国生产了全球一半以上的新分子。此外,根据 EFPIA 的数据,2021 年,北美占全球药品销售额的 49.1%,而欧洲为 23.4%。

同样,根据 EFPIA 的数据,与欧盟前五市场和美国市场相比,巴西、中国和印度製药业在 2016-2021 年期间分别成长了 11.7%、6.7% 和 11.8%,平均市场成长率分别为5.8 %和5.6%。此外,根据印度品牌资产基金会 (IBEF) 的数据,印度是全球製药业的一个主要且正在崛起的参与者。该国是世界上最大的仿製药贸易国,占全球供应量的近20%。它供应了全球约 50% 的疫苗接种需求。国内製药业包括 3,000 家製药公司和约 10,500 个製造单位。根据印度政府的官方数据,印度医药产业价值近500亿美元,其中超过250亿美元来自出口。印度占世界仿製药出口的 20% 左右。此外,日本是世界上最大的药品市场之一。根据日本厚生劳动省(MHLW)年度药品生产统计数据,2020 年日本处方药和非处方药市场规模为 1,070 亿美元。

随着产业的不断发展和创新,对能够支持个人化疫苗开发的佐剂的需求不断增加,推动人类疫苗佐剂市场的显着成长和投资。因此,全球不断成长的製药业可能会在未来几年为人类疫苗佐剂市场创造利润丰厚的成长机会。

阻碍人类疫苗佐剂市场的因素

人用疫苗佐剂的製造是一个复杂的过程,涉及严格的监管要求和品质控制措施。佐剂的生产需要专门的设备和设施,并严格遵守良好生产规范(GMP)和其他监管标准,以确保最终产品的纯度、安全性和功效。由于满足这些要求的资源和专业知识有限,这可能会给製造商,特别是小型公司或新进入者带来重大挑战。

监管挑战也在限制人用疫苗佐剂市场方面发挥重要作用。佐剂被认为是疫苗的关键组成部分,受到欧洲药品管理局(EMA)和美国食品药物管理局(FDA)等卫生当局的严格监管。佐剂的监管审批过程可能漫长而复杂,需要大量的临床前和临床资料来证明安全性、有效性和品质。它可能对製造商构成重大障碍,因为获得监管部门批准所需的成本和时间可能相当大。因此,上述因素阻碍了人用疫苗佐剂市场的成长。

人用疫苗佐剂市场:细分概述

依类型,人用疫苗佐剂市场分为颗粒佐剂、乳液佐剂、组合佐剂等。颗粒佐剂细分市场将在 2022 年占据更大的市场份额。然而,乳液佐剂细分市场预计从 2022 年至 2030 年将在市场上实现更高的CAGR。颗粒佐剂由颗粒组成,通常为奈米或微米尺寸,旨在模仿病原体或细胞结构,刺激强大的免疫反应。这些佐剂增强免疫细胞对抗原的摄取并促进免疫活化。颗粒佐剂的着名例子包括铝盐(明矾),几十年来一直用于人类疫苗中以增强抗体反应,以及新开发的产品,例如病毒样颗粒(VLP)和基于奈米颗粒的佐剂。

依应用,人用疫苗佐剂市场分为流感、肝炎、人类乳突病毒(HPV)等。流感细分市场在 2022 年占据最大市场份额,预计 2022 年至 2030 年市场复合CAGR最高。流感疫苗对于预防季节性流感爆发和潜在大流行至关重要。它们针对的是一种快速进化的病毒,需要不断更新疫苗以匹配流行的病毒株。流感疫苗中使用的佐剂可增强免疫反应,特别是在老年人或免疫功能低下的个体等高风险族群。它们也支持广泛保护性、交叉反应性免疫反应的发展。

就最终用户而言,人用疫苗佐剂市场分为製药和生技公司、CMO 和 CRO 等。製药和生物技术公司细分市场在 2022 年占据最大份额,预计 2022 年至 2030 年CAGR最高。製药和生物技术公司在疫苗的研究、开发和商业化中发挥核心作用,包括针对多种传染病和健康状况的佐剂疫苗製剂。这些公司处于疫苗创新的前沿,在临床前和临床开发阶段推动佐剂技术、候选疫苗和佐剂疫苗配方的发现和优化。

人类疫苗佐剂市场:地理概况

2022年,北美占据全球最大的人用疫苗佐剂市场。美国在北美人用疫苗佐剂市场中占有重要份额。该国的市场成长主要归因于政府医疗保健支出的增加以及对新型疫苗配方的需求激增,以更有效地治疗传染病。根据美国医疗保险和医疗补助服务中心的数据,2021 年美国国民医疗保健支出成长 2.7%,达到 4.3 兆美元,即人均 12,914 美元。医疗卫生支出占全国GDP的18.3%。美国卫生与公众服务部预计,2019-2028年国家卫生支出将以年均5.4%的速度成长,到2028年将达到6.2兆美元。卫生支出的上升可能导致资金配置增加用于疫苗的研发,刺激了对人用疫苗佐剂的需求。

根据 2020 年 7 月发布的全球疾病负担研究的新发现,美国的非传染性疾病和传染病负担巨大且不断增加。据约翰霍普金斯大学称,近二十年来,美国SARS、莱姆病、登革热、西尼罗河病毒、寨卡病毒等疾病感染病例迅速增加。此外,同一消息来源也证实,疟疾、结核病、霍乱、百日咳、流感、肺炎球菌疾病和淋病等重新出现的疾病的发生率增加。同样,根据美国疾病管制与预防中心 (CDC) 的数据,2010 年至 2022 年间,流感每年导致 100,000 至 710,000 人住院治疗,4,900 至 52,000 人死亡。根据 ICO/IARC 资讯中心 2023 年 HPV 和癌症报告有1.405 亿15 岁及以上女性面临HPV 相关子宫颈癌的风险。在美国普通人群中,预计有近 3.9% 的女性在特定时间携带子宫颈 HPV16/18 感染,71.2% 的浸润性子宫颈癌归因于 HPV 16 或 18。感染和重新出现的疾病推动了公司在疫苗开发方面的努力,推动了美国人类疫苗佐剂市场的成长。

美国政府努力为国内药品和保健产品的开发和商业化创造有利的环境。该国拥有多个潜在的製药和医疗器材市场参与者,包括辉瑞、诺华、波士顿科学、Integra LifeSciences、安进和雅培,其製药和医疗器材行业创新拥有各种专利。因此,各製药巨头药物开发活动的增加提振了美国的人用疫苗佐剂市场。

在准备人类疫苗佐剂市场报告时提到的一些主要一手和二手来源包括世界银行数据、国家卫生服务体系 (NHS)、FDA(食品和药物管理局)、EMA(欧洲药品管理局)和WHO(世界卫生组织)。

目录

第 1 章:简介

第 2 章:执行摘要

  • 重要见解

第 3 章:研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章:人用疫苗佐剂市场格局

  • 概述
  • PEST分析

第 5 章:人类疫苗佐剂市场 - 主要市场动态

  • 人类疫苗佐剂市场 - 主要市场动态
  • 市场驱动因素
    • 慢性病盛行率上升
    • 越来越关注免疫计划
  • 市场限制
    • 製造复杂性和监管挑战
  • 市场机会
    • 不断发展的製药业
  • 未来的趋势
    • 个人化疫苗的上升趋势
  • 驱动因素和限制的影响:

第 6 章:人类疫苗佐剂市场 - 全球市场分析

  • 人类疫苗佐剂市场收入,2022 - 2030
  • 人用疫苗佐剂市场预测分析

第 7 章:人类疫苗佐剂市场分析 - 按类型

  • 颗粒佐剂
  • 乳化助剂
  • 组合佐剂
  • 其他的

第 8 章:人类疫苗佐剂市场分析 -按应用

  • 流感
  • 肝炎
  • 人类乳突病毒(HPV)
  • 其他的

第 9 章:人类疫苗佐剂市场分析 - 按最终用户

  • 製药和生物技术公司
  • CMO 和 CRO
  • 其他的

第 10 章:人类疫苗佐剂市场 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章:产业格局

  • 概述

第 12 章:公司简介

  • Novartis AG
  • Dynavax Technologies Corp
  • CSL Ltd
  • Seppic SA
  • SPI Pharma Inc
  • Hawaii Biotech Inc
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp
  • Creative Biolabs Inc

第 13 章:附录

Product Code: TIPRE00020517

The global human vaccine adjuvants market is expected to reach US$ 4.489 billion in 2030 from US$ 1.571 billion in 2022. The market is estimated to grow with a CAGR of 14.0% from 2022 to 2030. Key factors driving the human vaccine adjuvants market growth include the rising prevalence of chronic diseases and growing focus on immunization programs.

Market Opportunities of Human Vaccine Adjuvants Market

The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry's increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases.

The US has one of the most R&D-intensive pharmaceutical industries globally. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the North America market (US and Canada) remained the world's largest market with a 49.1% share, well ahead of Europe, China, and Japan. The US is the global leader in innovative R&D investments, and the country produced over half of the world's new molecules in the last decade. Additionally, as per EFPIA, in 2021, North America accounted for 49.1% of global pharmaceutical sales, compared with 23.4% for Europe.

Similarly, according to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion.

As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the human vaccine adjuvants market in the coming years.

Factors Hampering Human Vaccine Adjuvants Market

Manufacturing human vaccine adjuvant is a complex process involving stringent regulatory requirements and quality control measures. The production of adjuvants requires specialized equipment and facilities with strict adherence to Good Manufacturing Practices (GMP) and other regulatory standards to ensure the final product's purity, safety, and efficacy. This can pose significant challenges for manufacturers, especially smaller companies or new entrants, owing to limited resources and expertise to meet these requirements.

Regulatory challenges also play a significant role in restraining the human vaccine adjuvants market. Adjuvants are considered critical components of vaccines, and they are subjected to strict regulatory oversight by health authorities such as the European Medicines Agency (EMA) in Europe and the Food and Drug Administration (FDA) in the US. The regulatory approval process for adjuvants can be lengthy and complex, requiring extensive preclinical and clinical data to demonstrate safety, efficacy, and quality. It can pose a significant barrier for manufacturers, as the cost and time required to obtain regulatory approval can be substantial. Thus, the factors mentioned above hamper the growth of the human vaccine adjuvants market.

Human Vaccine Adjuvants Market: Segmental Overview

Based on type, the human vaccine adjuvants market is segmented into particulate adjuvants, emulsion adjuvants, combination adjuvants, and others. The particulate adjuvant segment held a larger share of the market in 2022. However, the emulsion adjuvants segment is expected to register a higher CAGR in the market from 2022 to 2030. Particulate adjuvants consist of particles, often of nanometer or micrometer size, designed to mimic pathogens or cellular structures, stimulating a robust immune response. These adjuvants enhance antigen uptake by immune cells and promote immune activation. Notable examples of particulate adjuvants include aluminum salts (Alum), which have been used for decades in human vaccines to enhance antibody responses, and newer developments such as virus-like particles (VLPs) and nanoparticle-based adjuvants.

By application, the human vaccine adjuvants market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Influenza vaccines are crucial for preventing seasonal flu outbreaks and potential pandemics. They target a rapidly evolving virus, requiring continual vaccine updating to match circulating strains. Adjuvants used in influenza vaccines enhance immune responses, particularly in high-risk populations such as the elderly or immunocompromised individuals. They also support the development of broadly protective, cross-reactive immune responses.

In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Pharmaceutical and biotechnology companies play a central role in the research, development, and commercialization of vaccines, including adjuvanted vaccine formulations, targeting diverse infectious diseases and health conditions. These companies are at the forefront of vaccine innovation, driving the discovery and optimization of adjuvant technologies, vaccine candidates, and adjuvanted vaccine formulations through preclinical and clinical development stages.

Human Vaccine Adjuvants Market: Geographical Overview

North America accounted for the largest global human vaccine adjuvants market share in 2022. The US holds a significant share of North America's human vaccine adjuvants market. The market growth in this country is mainly ascribed to rising government spending on healthcare and a surging demand for novel vaccine formulations to treat infectious diseases more efficiently. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019-2028, reaching US$ 6.2 trillion by 2028. The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants.

According to new findings derived from the Global Burden of Disease study published in July 2020, there is a large and increasing burden of noncommunicable and infectious diseases in the US. According to Johns Hopkins University, the cases of diseases such as SARS, Lyme disease, dengue fever, West Nile virus, and Zika virus infection have increased rapidly in the last two decades in the US. Also, the same source affirmed an increase in the incidence of re-emerging diseases such as malaria, tuberculosis, cholera, pertussis, influenza, pneumococcal disease, and gonorrhea. Similarly, according to the Centers for Disease Control and Prevention (CDC), flu has resulted in 100,000 to 710,000 hospitalizations and 4,900 to 52,000 deaths annually between 2010 and 2022. According to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, the US has a population of 140.5 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Nearly 3.9% of women in the US in the general population are projected to harbor cervical HPV16/18 infection at a given time, and 71.2% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, a rise in the incidences of various infections and re-emerging diseases boosts companies' efforts in vaccine development, fueling the human vaccine adjuvants market growth in the US.

The US government strives to create a conducive environment for developing and commercializing pharmaceutical and healthcare products in the country. The country has several potential pharmaceutical and medical device market players, including Pfizer, Novartis, Boston Scientific, Integra LifeSciences, Amgen, and Abbott, with various patents for their pharmaceutical and medical device industry innovations. Thus, an increase in drug development activities by various pharmaceutical giants bolsters the human vaccine adjuvants market in the US.

A few of the major primary and secondary sources referred to while preparing the report on the human vaccine adjuvants market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the human vaccine adjuvants market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.  
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the human vaccine adjuvants market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Human Vaccine Adjuvants Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Human Vaccine Adjuvants Market - Key Market Dynamics

  • 5.1 Human Vaccine Adjuvants Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Diseases
    • 5.2.2 Growing Focus on Immunization Programs
  • 5.3 Market Restraints
    • 5.3.1 Manufacturing Complexities and Regulatory Challenges
  • 5.4 Market Opportunities
    • 5.4.1 Growing Pharmaceutical Industry
  • 5.5 Future Trends
    • 5.5.1 Rising Trend of Personalized Vaccines
  • 5.6 Impact of Drivers and Restraints:

6. Human Vaccine Adjuvants Market - Global Market Analysis

  • 6.1 Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
  • 6.2 Human Vaccine Adjuvants Market Forecast Analysis

7. Human Vaccine Adjuvants Market Analysis - by Type

  • 7.1 Particulate Adjuvant
    • 7.1.1 Overview
    • 7.1.2 Particulate Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Emulsion Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Emulsion Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Combination Adjuvant
    • 7.3.1 Overview
    • 7.3.2 Combination Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Human Vaccine Adjuvants Market Analysis - by Application

  • 8.1 Influenza
    • 8.1.1 Overview
    • 8.1.2 Influenza: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Hepatitis
    • 8.2.1 Overview
    • 8.2.2 Hepatitis: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Human papilloma virus (HPV)
    • 8.3.1 Overview
    • 8.3.2 Human papilloma virus (HPV): Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Human Vaccine Adjuvants Market Analysis - by End User

  • 9.1 Pharmaceutical and Biotechnology Companies
    • 9.1.1 Overview
    • 9.1.2 Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.2 CMOs and CROs
    • 9.2.1 Overview
    • 9.2.2 CMOs and CROs: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

10. Human Vaccine Adjuvants Market - Geographical Analysis

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America Human Vaccine Adjuvants Market Overview
    • 10.2.2 North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    • 10.2.3 North America: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.2.3.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.2.4 North America: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.2.4.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.2.5 North America: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.2.5.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.2.6 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.2.6.2 United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.2.6.2.1 United States: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.2.6.2.2 United States: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.2.6.2.3 United States: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.2.6.3 Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.2.6.3.1 Canada: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.2.6.3.2 Canada: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.2.6.3.3 Canada: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.2.6.4 Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.2.6.4.1 Mexico: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.2.6.4.2 Mexico: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.2.6.4.3 Mexico: Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.3 Europe
    • 10.3.1 Europe Human Vaccine Adjuvants Market Overview
    • 10.3.2 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    • 10.3.3 Europe: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.3.3.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.3.4 Europe: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.3.4.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.3.5 Europe: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.5.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.3.6 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.3.6.2 Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.2.1 Germany: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.2.2 Germany: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.2.3 Germany: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.3 United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.3.1 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.3.2 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.3.3 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.4 France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.4.1 France: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.4.2 France: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.4.3 France: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.5 Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.5.1 Italy: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.5.2 Italy: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.5.3 Italy: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.6 Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.6.1 Spain: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.6.2 Spain: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.6.3 Spain: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.3.6.7 Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.3.6.7.1 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.3.6.7.2 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.3.6.7.3 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Human Vaccine Adjuvants Market Overview
    • 10.4.2 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    • 10.4.3 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.4.3.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.4.4 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.4.4.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.4.5 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.5.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.4.6 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.4.6.2 China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.2.1 China: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.2.2 China: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.2.3 China: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.3 Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.3.1 Japan: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.3.2 Japan: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.3.3 Japan: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.4 India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.4.1 India: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.4.2 India: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.4.3 India: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.5 Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.5.1 Australia: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.5.2 Australia: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.5.3 Australia: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.6 South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.6.1 South Korea: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.6.2 South Korea: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.6.3 South Korea: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.4.6.7 Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.4.6.7.1 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.4.6.7.2 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.4.6.7.3 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.5 Middle East and Africa
    • 10.5.1 Middle East and Africa Human Vaccine Adjuvants Market Overview
    • 10.5.2 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    • 10.5.3 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.5.3.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.5.4 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.5.4.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.5.5 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.5.5.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.5.6 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.5.6.2 Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.5.6.2.1 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.5.6.2.2 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.5.6.2.3 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.5.6.3 South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.5.6.3.1 South Africa: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.5.6.3.2 South Africa: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.5.6.3.3 South Africa: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.5.6.4 United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.5.6.4.1 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.5.6.4.2 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.5.6.4.3 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.5.6.5 Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.5.6.5.1 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.5.6.5.2 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.5.6.5.3 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.6 South and Central America
    • 10.6.1 South and Central America Human Vaccine Adjuvants Market Overview
    • 10.6.2 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 | (US$ Million)
    • 10.6.3 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.6.3.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 10.6.4 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.6.4.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
    • 10.6.5 South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.6.5.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
    • 10.6.6 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 10.6.6.2 Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.6.6.2.1 Brazil: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.6.6.2.2 Brazil: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.6.6.2.3 Brazil: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.6.6.3 Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.6.6.3.1 Argentina: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.6.6.3.2 Argentina: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.6.6.3.3 Argentina: Human Vaccine Adjuvants Market Breakdown, by End User
      • 10.6.6.4 Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.6.6.4.1 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
        • 10.6.6.4.2 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
        • 10.6.6.4.3 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User

11. Industry Landscape

  • 11.1 Overview

12. Company Profiles

  • 12.1 Novartis AG
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Dynavax Technologies Corp
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 CSL Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Seppic SA
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 SPI Pharma Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Hawaii Biotech Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Croda International Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Novavax Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Phibro Animal Health Corp
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Creative Biolabs Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Human Vaccine Adjuvants Market Segmentation
  • Table 2. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 4. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
  • Table 5. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
  • Table 6. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 7. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 8. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 9. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 10. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 11. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 12. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 13. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 14. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 15. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 16. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 17. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 18. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 19. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 20. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 21. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 22. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 23. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 24. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 25. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 26. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 27. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 28. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 29. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 30. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 31. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 32. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 33. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 34. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 35. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 36. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 37. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 38. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 39. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 40. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 41. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 42. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 43. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 44. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 45. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 46. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 47. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 48. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 49. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 50. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 51. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 52. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 53. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 54. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 55. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 56. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 57. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 58. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 59. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 60. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 61. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 62. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 63. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 64. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 65. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 66. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 67. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 68. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 69. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 70. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 71. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 72. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 73. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 74. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 75. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 76. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 77. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 78. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 79. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 80. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 81. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 82. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 83. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 84. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 85. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 86. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 87. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 88. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 89. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
  • Table 90. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
  • Table 91. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
  • Table 92. Recent Growth Strategies in the Human Vaccine Adjuvants Market
  • Table 93. Glossary of Terms, Global Human Vaccine Adjuvants Market

List Of Figures

  • Figure 1. Human Vaccine Adjuvants Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Human Vaccine Adjuvants Market Breakdown by Geography, 2022 and 2030 (%)
  • Figure 5. Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
  • Figure 6. Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 7. Particulate Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Emulsion Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Combination Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
  • Figure 12. Influenza: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Hepatitis: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Human papilloma virus (HPV): Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
  • Figure 17. Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. CMOs and CROs: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Human Vaccine Adjuvants Market Breakdown by Region, 2022 and 2030 (%)
  • Figure 21. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 22. North America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 23. North America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 24. North America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 25. North America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 26. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 27. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Europe: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 31. Europe: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 32. Europe: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 33. Europe: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 34. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 35. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 36. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 37. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 38. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 39. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 40. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 41. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 42. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 43. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 44. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 45. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 46. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 47. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 48. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 49. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 50. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 51. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 52. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 53. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 54. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 55. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 56. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 57. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 58. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 59. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 60. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 61. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
  • Figure 62. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
  • Figure 63. South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
  • Figure 64. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 65. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 66. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 67. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)